Shares of Nutriband Inc. (NASDAQ:NTRB - Get Free Report) shot up 4.5% during trading on Friday . The company traded as high as $8.49 and last traded at $8.11. 52,674 shares were traded during mid-day trading, a decline of 41% from the average session volume of 89,186 shares. The stock had previously closed at $7.76.
Nutriband Price Performance
The stock has a 50-day simple moving average of $7.37 and a 200 day simple moving average of $6.56. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.48 and a current ratio of 3.71. The company has a market cap of $90.43 million, a P/E ratio of -9.01 and a beta of 1.15.
Nutriband (NASDAQ:NTRB - Get Free Report) last announced its quarterly earnings data on Friday, May 30th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. Nutriband had a negative return on equity of 68.25% and a negative net margin of 415.93%. The company had revenue of $0.67 million during the quarter, compared to the consensus estimate of $0.71 million. On average, equities analysts expect that Nutriband Inc. will post -0.6 EPS for the current year.
Hedge Funds Weigh In On Nutriband
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of Nutriband by 7.5% during the 4th quarter. Geode Capital Management LLC now owns 62,435 shares of the company's stock worth $294,000 after buying an additional 4,372 shares during the period. Consolidated Portfolio Review Corp bought a new position in shares of Nutriband during the 2nd quarter worth approximately $81,000. Finally, US Bancorp DE bought a new position in shares of Nutriband during the 1st quarter worth approximately $29,000. Institutional investors own 19.70% of the company's stock.
About Nutriband
(
Get Free Report)
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nutriband, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutriband wasn't on the list.
While Nutriband currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
